Achilles Degeneration, Achilles Tendinitis, Achilles Tendinitis, Left Leg, Achilles Tendinitis, Right Leg, Achilles Tendon Thickening, Tendinopathy
Conditions
Keywords
Achilles Tendinopathy, Autologous Stem Cells, Musculoskeletal
Brief summary
This study is looking at a new treatment, using the patient's own stem cells (the repair cells of the body), to see whether this can help reduce pain and promote healing of the Achilles tendon, without side effects.
Detailed description
Tendon disorders compromise pain free activity and often progress to chronic pain with a major impact on quality of life. More than 85,000 patients each year see their general practitioner (GP) with Achilles Tendinopathy (AT) which affects the lower leg in young and middle aged adults. The main treatment is physiotherapy, although surgery is eventually considered in 25-45%of patients, an intervention that requires several months of immobilisation and has unpredictable outcomes. Other treatments include, shockwave therapy, Platelet Rich Plasma (PRP) (a blood injection of platelet rich plasma) and steroid injections, but other than physiotherapy non have been shown to be better than placebo. There is a need for improved nonsurgical treatments. There is an established treatment in horses that involves injection of the horses own stem cells into the tendon, which has been shown to be effective but has never been used in man. We wish to translate the technology to humans and propose a pilot phase II trial to establish the safety of stem cells implanted in diseased human tendon. We aim to study 10 patients with chronic mid substance achilles tendinopathy to assess safety as our primary outcome measure. In addition we capture clinical outcomes scores and ultrasound appearances. Other than the stem cell injection, all assessments will be non invasive. Participants will be otherwise healthy adults, aged 18-70 and recruited from routine outpatient clinics at the Royal National Orthopaedic Hospital, presenting with a painful heel, diagnosed by a specialist as Achilles tendinopathy, and having already undergone a minimum of 6 months of physiotherapy. Each participant will have 6 months follow up. This study will help inform a larger clinical trial in the future for which a further ethics application will be made.
Interventions
BIOLOGICALAutologous Mesenchymal Stem Cells
Sponsors
University College, London
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Aged ≥18 and ≤ 70 (both males and females) * Participants with chronic midportion AT (as defined by pain in region of AT and tender swelling in mid portion of AT (no tenderness over bony attachment to heel) with symptoms for longer than 6 months who have failed conservative treatment (at least a full course of physiotherapy) and for whom surgery is being considered * Able to provide written informed consent
Exclusion criteria
* Previous bony surgery (e.g. reconstructive pelvic osteotomy) at or in proximity to the bone marrow harvest site * Pregnancy or lactation * Current use of steroids, anti-tumour necrosis factor (TNF) drugs, methotrexate, or ciprofloxacin (or use within 4 weeks of assessment for eligibility) * Positive for hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Immunodeficiency Virus (HIV 1 and 2), syphilis and human t-cell leukaemia virus (HTLV) * Previous AT surgery on the tendon to receive mesenchymal stem cell (MSC) implantation * Inflammatory arthritis * Known or suspected underlying haematological malignancy * Other active malignancy in the past 3 years * Bovine or antibiotic allergy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary safety outcome will be the incidence rate of Serious Adverse Reaction (SAR). | 6 months | The primary safety outcome is the incidence rate of SARs. This will be expressed as the proportion of participants experiencing a SAR at any time over the 24 week follow-up period. Primary outcomes will be assessed by adverse events reporting, clinical assessment and ultrasound. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of success | 6 months | The secondary efficacy outcome measure is the incidence of success at 6 months, where success is defined as a reduction of 2 or more points on VAS of pain and an increase of VISA-A score greater than the Minimum Clinically Important Difference (MCID). |
| Conventional ultrasound changes from baseline | Baseline immediately before implantation and at weeks 6, 12 and 24 | — |
| Ultrasound Tissue Characterisation (UTC) changes from baseline | Baseline immediately before implantation and at weeks 6, 12 and 24 | — |
| Inter-observer reliability of UTC against conventional US | Baseline immediately before implantation and at weeks 6, 12 and 24 | — |
Countries
United Kingdom
Contacts
Primary ContactAndy Goldberg
Outcome results
None listed